Table 2. Inhibition of rLipGMTB after a 30-min incubation period with each inhibitor1.
| Compounds | % inhibition | xI50 | |
|---|---|---|---|
| xI = 4 | xI = 100 | ||
| MmPPOX | 54.1 ± 1.5 | 82.0 ± 3.8 | 3.1 |
| iBpPPOX | 40.5 ± 3.1 | 60.6 ± 0.22 | 14.7 |
| iBPOX | 32.7 ± 0.70 | 80.3 ± 0.90 | 15.0 |
| HpPPOX | 61.8 ± 4.7 | 73.8 ± 1.0 | 3.5 |
| HPOX | 58.5 ± 1.4 | 93.8 ± 5.7 | 2.9 |
| BePOX | 9.8 ± 0.28 | 68.8 ± 1.1 | 12.5 |
| CyC7α | 47.4 ± 0.81 | 81.4 ± 1.6 | 5.0 |
| CyC7β | 7.9 ± 0.72 | 57.6 ± 2.0 | 48.1 |
| CyC8α | 2.5 ± 0.10 | 51.3 ± 2.6 | 58.5 |
| CyC8β | 3.2 ± 0.16 | 32.0 ± 1.5 | >200 |
| CyC17 | 66.4 ± 4.5 | 95.4 ± 2.6 | 0.98 |
| Orlistat | 10.8 ± 0.17 | 69.5 ± 5.3 | 15.2 |
1
Inhibition data (% of initial activity), at inhibitor molar excess (xI) of 4 and 100 related to 1 mol of enzyme. Results are expressed as mean values ± S.D. of at least three independent assays. The inhibitor molar excess leading to 50% lipase inhibition, xI50, was determined as described in Experimental procedures section.